GENERIC NAME: eribulin mesylate
BRAND NAME: Halaven
Microtubules are dynamic intracellular structures that are responsible for various kinds of movements including cell division, organization of intracellular structure, and intracellular transport. Eribulin inhibits the growth phase of microtubules, consequently interfering with cell growth and function and eventually causing cancer cell death. Eribulin was developed from a chemical first isolated from the rare marine sponge, Halichondria okadai.
Eribulin can help some patients with metastatic breast cancer live longer. In one trial, women treated with eribulin lived about 2.5 months longer than women who received other treatments. Eribulin was approved by the FDA in 2010.
PRESCRIBED FOR: Eribulin is a prescription chemotherapy medicine used to treat patients with metastatic breast cancer. Eribulin should only be used in patients who have already received at least 2 other types of anti-cancer medicines, including an anthracycline and a taxane.
SIDE EFFECTS: The most common side effects of eribulin are:
- low white blood cells,
- low red blood cells,
- hair loss,
- nausea, and
- numbness, tingling, or burning in the hands and feet (peripheral neuropathy).
Quick GuideBreast Cancer Diagnosis and Treatment
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Need help identifying pills and medications?
Use the pill identifier tool on RxList.